Evaluating the performance of fibronectin 1 (FN1), integrin α4β1 (ITGA4), syndecan-2 (SDC2), and glycoprotein CD44 as the potential biomarkers of oral squamous cell carcinoma (OSCC)

Biomarkers

Volumn 18, Issue 1, 2013, Pages 63-72

  Yen, Ching Yu ^a,b   Huang, Chien Yang ^c   Hou, Ming Feng ^c,d,e,f   Yang, Yi Hsin ^c   Chang, Chao Hsiang ^d   Huang, Hurng Wern ^f   Chen, Chung Ho ^c   Chang, Hsueh Wei ^c,d  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^f NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Extracellular matrix; Fibronectin 1; Glycoprotein CD44; Integrin 4 1; Oral squamous cell carcinoma; Receiver operating characteristic curves; Syndecan 2; Tumor marker

Indexed keywords

FIBRONECTIN; FIBRONECTIN 1; HERMES ANTIGEN; MESSENGER RNA; SYNDECAN 2; UNCLASSIFIED DRUG; VERY LATE ACTIVATION ANTIGEN 4;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RISK; CONTROLLED STUDY; EDENTULOUSNESS; EXTRACELLULAR MATRIX; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOUTH; MOUTH SQUAMOUS CELL CARCINOMA; SENSITIVITY AND SPECIFICITY; TONGUE; TUMOR LOCALIZATION;

ADULT; ANTIGENS, CD44; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; FEMALE; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA4BETA1; MALE; MIDDLE AGED; MOUTH; MOUTH NEOPLASMS; SENSITIVITY AND SPECIFICITY; SYNDECAN-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84872511285     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.737025     Document Type: Article

References (80)

1. Andreoli V, Cittadella R, Valentino P, Condino F, La Russa A, Liguori M, Manna I, Spadafora P, Nistico R, Pirritano D, Clodomiro A, Quattrone A. (2007). The role of VLA4 polymorphisms in multiple sclerosis: An association study. J Neuroimmunol 189:125-128.
2. Anwar AR, Walsh GM, Cromwell O, Kay AB, Wardlaw AJ. (1994). Adhesion to fibronectin primes eosinophils via α4β1 (VLA-4). Immunology 82:222-228.
3. Assimakopoulos D, Kolettas E, Patrikakos G, Evangelou A. (2002). The role of CD44 in the development and prognosis of head and neck squamous cell carcinomas. Histol Histopathol 17:1269-1281.
4. Beauvais DM, Rapraeger AC. (2004). Syndecans in tumor cell adhesion and signaling. Reprod Biol Endocrinol 2:3.
5. Brahmachari S, Pahan K. (2010). Gender-specific expression of β1 integrin of VLA-4 in myelin basic protein-primed T cells: Implications for gender bias in multiple sclerosis. J Immunol 184:6103-6113.
6. Buggins AG, Levi A, Gohil S, Fishlock K, Patten PE, Calle Y, Yallop D, Devereux S. (2011). Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 154:216-222.
7. Chan BM, Elices MJ, Murphy E, Hemler ME. (1992). Adhesion to vascular cell adhesion molecule 1 and fibronectin. Comparison of α 4 β 1 (VLA-4) and α 4 β 7 on the human B cell line JY. J Biol Chem 267:8366-8370.
8. Chang HW, Cheng CA, Gu DL, Chang CC, Su SH, Wen CH, Chou YC, Chou TC, Yao CT, Tsai CL, Cheng CC. (2008). High-throughput avian molecular sexing by SYBR green-based real-time PCR combined with melting curve analysis. BMC Biotechnol 8:12.
9. Chang E, Park DI, Kim YJ, Kim BK, Park JH, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Kim HD, Kim DH, Kim YH. (2010). Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: A preliminary report in Korean patients. Hepatogastroenterology 57:720-727.
10. Chaudhary AK, Pandya S, Mehrotra R, Bharti AC, Jain S, Singh M. (2010). Functional polymorphism of the MMP-1 promoter (-1607 1G/2G) in potentially malignant and malignant head and neck lesions in an Indian population. Biomarkers 15:684-692.
11. Chaudhary AK, Pandya S, Mehrotra R, Singh M, Singh M. (2011). Role of functional polymorphism of matrix metalloproteinase-2 (-1306 C/T and -168 G/T) and MMP-9 (-1562 C/T) promoter in oral submucous fibrosis and head and neck squamous cell carcinoma in an Indian population. Biomarkers 16:577-586.
12. Chien MH, Ying TH, Hsieh YH, Lin CH, Shih CH, Wei LH, Yang SF. (2012). Tumor-associated carbonic anhydrase XII is linked to the growth of primary oral squamous cell carcinoma and its poor prognosis. Oral Oncol 48:417-423.
13. Chiquet BT, Hashmi SS, Henry R, Burt A, Mulliken JB, Stal S, Bray M, Blanton SH, Hecht JT. (2009). Genomic screening identifies novel linkages and provides further evidence for a role of MYH9 in nonsyndromic cleft lip and palate. Eur J Hum Genet 17:195-204.
14. Choi Y, Kim H, Chung H, Hwang JS, Shin JA, Han IO, Oh ES. (2010). Syndecan-2 regulates cell migration in colon cancer cells through Tiam1-mediated Rac activation. Biochem Biophys Res Commun 391:921-925.
15. Chong HC, Tan CK, Huang RL, Tan NS. (2012). Matricellular proteins: A sticky affair with cancers. J Oncol 2012:351089.
16. Desgrosellier JS, Cheresh DA. (2010). Integrins in cancer: Biological implications and therapeutic opportunities. Nat Rev Cancer 10:9-22.
17. Devriese LA, Bosma AJ, van de Heuvel MM, Heemsbergen W, Voest EE, Schellens JH. (2012). Circulating tumor cell detection in advanced non-small cell lung cancer patients by multi-marker QPCR analysis. Lung Cancer 75:242-247.
18. Elahi M, Rakhshan V, Ghasemian NT, Moshref M. (2012). Prognostic value of transforming growth factor β 1 [TGF-s1] and matrix metalloproteinase 9 [MMP-9] in oral squamous cell carcinoma. Biomarkers 17:21-27.
19. Essner JJ, Chen E, Ekker SC. (2006). Syndecan-2. Int J Biochem Cell Biol 38:152-156.
20. Fabris M, Quartuccio L, Salvin S, Pozzato G, De Re V, Mazzaro C, Ferri C, Baldini C, De Vita S. (2008). Fibronectin gene polymorphisms are associated with the development of B-cell lymphoma in type II mixed cryoglobulinemia. Ann Rheum Dis 67:80-83.
21. Faria PC, Sena AA, Nascimento R, Carvalho WJ, Loyola AM, Silva SJ, Durighetto AF, Oliveira AD, Oliani SM, Goulart LR. (2010). Expression of annexin A1 mRNA in peripheral blood from oral squamous cell carcinoma patients. Oral Oncol 46:25-30.
22. Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, Carraway KL, Hamilton K, Singal R, Goodwin WJ. (2007). Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 16:1348-1355.
23. Gao K, Zhou H, Zhang L, Lee JW, Zhou Q, Hu S, Wolinsky LE, Farrell J, Eibl G, Wong DT. (2009). Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS ONE 4:e5875.
24. Garmy-Susini B, Avraamides CJ, Schmid MC, Foubert P, Ellies LG, Barnes L, Feral C, Papayannopoulou T, Lowy A, Blair SL, Cheresh D, Ginsberg M, Varner JA. (2010). Integrin α4β1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res 70:3042-3051.
25. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M (eds.). (2002). AJCC Cancer Staging Manual. New York: Springer. \
26. Grimm M, Krimmel M, Polligkeit J, Alexander D, Munz A, Kluba S, Keutel C, Hoffmann J, Reinert S, Hoefert S. (2012). ABCB5 expression and cancer stem cell hypothesis in oral squamous cell carcinoma. Eur J Cancer. [Epub ahead of print] PMID: 22784549. DOI: 10.1016/j.ejca.2012.05.027.
27. Gupta N, Kakkar N, Vasishta RK. (2006). Pattern of fibronectin in hepatocellular carcinoma and its significance. Indian J Pathol Microbiol 49:362-364.
28. Han I, Park H, Oh ES. (2004). New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells. J Mol Histol 35:319-326.
29. Heymann GA, Carstanjen D, Kiesewetter H, Salama A. (2004). Polymorphism of the α4-subunit of VLA-4 integrin and bone marrow transplantation. Haematologica 89:882-884.
30. Huang X, Xiao DW, Xu LY, Zhong HJ, Liao LD, Xie ZF, Li EM. (2009). Prognostic significance of altered expression of SDC2 and CYR61 in esophageal squamous cell carcinoma. Oncol Rep 21:1123-1129.
31. Iczkowski KA. (2010). Cell adhesion molecule CD44: Its functional roles in prostate cancer. Am J Transl Res 3:1-7.
32. Jalkanen S, Jalkanen M. (1992). Lymphocyte CD44 binds the COOHterminal heparin-binding domain of fibronectin. J Cell Biol 116:817-825.
33. Jerhammar F, Ceder R, Garvin S, Grenman R, Grafstrom RC, Roberg K. (2011). Fibronectin 1 is a potential biomarker for radioresistance in head and neck squamous cell carcinoma. Cancer Biol Ther 10:1244-1251.
34. Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R. (2012). ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res 72:365-374.
35. Khan ZA, Caurtero J, Barbin YP, Chan BM, Uniyal S, Chakrabarti S. (2005). ED-B fibronectin in non-small cell lung carcinoma. Exp Lung Res 31:701-711.
36. Kim SH, Turnbull J, Guimond S. (2011). Extracellular matrix and cell signalling: The dynamic cooperation of integrin, proteoglycan and growth factor receptor. J Endocrinol 209:139-151.
37. Ko YC, Huang YL, Lee CH, Chen MJ, Lin LM, Tsai CC. (1995). Betel quid chewing, cigarette smoking and alcohol consumption related to oral cancer in Taiwan. J Oral Pathol Med 24:450-453.
38. Kosunen A, Pirinen R, Ropponen K, Pukkila M, Kellokoski J, Virtaniemi J, Sironen R, Juhola M, Kumpulainen E, Johansson R, Nuutinen J, Kosma VM. (2007). CD44 expression and its relationship with MMP-9, clinicopathological factors and survival in oral squamous cell carcinoma. Oral Oncol 43:51-59.
39. Kunimura T, Yoshida T, Sugiyama T, Morohoshi T. (2009). The Relationships Between Loss of Standard CD44 Expression and Lymph Node, Liver Metastasis in T3 Colorectal Carcinoma. J Gastrointest Cancer 40:115-118.
40. Kurtova AV, Tamayo AT, Ford RJ, Burger JA. (2009). Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting. Blood 113:4604-4613.
41. Kusano Y, Oguri K, Nagayasu Y, Munesue S, Ishihara M, Saiki I, Yonekura H, Yamamoto H, Okayama M. (2000). Participation of syndecan 2 in the induction of stress fiber formation in cooperation with integrin α5β1: Structural characteristics of heparan sulfate chains with avidity to COOH-terminal heparin-binding domain of fibronectin. Exp Cell Res 256:434-444.
42. Kusano Y, Yoshitomi Y, Munesue S, Okayama M, Oguri K. (2004). Cooperation of syndecan-2 and syndecan-4 among cell surface heparan sulfate proteoglycans in the actin cytoskeletal organization of Lewis lung carcinoma cells. J Biochem 135:129-137.
43. Labat-Robert J. (2012). Cell-Matrix interactions, the role of fibronectin and integrins. A survey. Pathol Biol 60:15-19.
44. Le Bras GF, Allison GL, Richards NF, Ansari SS, Washington MK, Andl CD. (2011). CD44 upregulation in E-cadherin-negative esophageal cancers results in cell invasion. PLoS ONE 6:e27063.
45. Lee KM, Han W, Kim JB, Shin I, Ko E, Park IA, Lee DS, Oh K, Noh DY. (2012). The CD49d+/high subpopulation from isolated human breast sarcoma spheres possesses tumor-initiating ability. Int J Oncol 40:665-672.
46. Lesley J, Hyman R, Kincade PW. (1993). CD44 and its interaction with extracellular matrix. Adv Immunol 54:271-335.
47. Livak KJ, Schmittgen TD. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402-408.
48. Luizon MR, de Almeida Belo V. (2012). Matrix metalloproteinase (MMP)-2 and MMP-9 polymorphisms and haplotypes as disease biomarkers. Biomarkers 17:286-288.
49. Marhaba R, Freyschmidt-Paul P, Zoller M. (2006). in vivo CD44-CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance. Eur J Immunol 36:3017-3032.
50. Markopoulos AK. (2012). Current aspects on oral squamous cell carcinoma. Open Dent J 6:126-130.
51. Marzioni D, Lorenzi T, Mazzucchelli R, Capparuccia L, Morroni M, Fiorini R, Bracalenti C, Catalano A, David G, Castellucci M, Muzzonigro G, Montironi R. (2009). Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int J Immunopathol Pharmacol 22:627-638.
52. Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, Watanabe M, Beppu T, Tamada M, Nagano O, Saya H, Baba H. (2012). CD44s regulates the TGF-s-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 72:3414-3423.
53. Munesue S, Yoshitomi Y, Kusano Y, Koyama Y, Nishiyama A, Nakanishi H, Miyazaki K, Ishimaru T, Miyaura S, Okayama M, Oguri K. (2007). A novel function of syndecan-2, suppression of matrix metalloproteinase-2 activation, which causes suppression of metastasis. J Biol Chem 282:28164-28174.
54. Nuckel H, Switala M, Collins CH, Sellmann L, Grosse-Wilde H, Duhrsen U, Rebmann V. (2009). High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol 131:472-480.
55. Popovic A, Demirovic A, Spajic B, Stimac G, Kruslin B, Tomas D. (2010). Expression and prognostic role of syndecan-2 in prostate cancer. Prostate Cancer Prostatic Dis 13:78-82.
56. Rajarajan A, Bloor BK, Desai H, Stokes A, Odell EW. (2008). Variant CD44 expression by human fibroblasts. Biomarkers 13:307-318.
57. Rebhun RB, Cheng H, Gershenwald JE, Fan D, Fidler IJ, Langley RR. (2010). Constitutive expression of the α4 integrin correlates with tumorigenicity and lymph node metastasis of the B16 murine melanoma. Neoplasia 12:173-182.
58. Ryu HY, Lee J, Yang S, Park H, Choi S, Jung KC, Lee ST, Seong JK, Han IO, Oh ES. (2009). Syndecan-2 functions as a docking receptor for pro-matrix metalloproteinase-7 in human colon cancer cells. J Biol Chem 284:35692-35701.
59. Ryu MH, Park HM, Chung J, Lee CH, Park HR. (2010). Hypoxia-inducible factor-1α mediates oral squamous cell carcinoma invasion via upregulation of α5 integrin and fibronectin. Biochem Biophys Res Commun 393:11-15.
60. Saito Y, Owaki T, Matsunaga T, Saze M, Miura S, Maeda M, Eguchi M, Tanaka R, Taira J, Kodama H, Goto S, Niitsu Y, Terada H, Fukai F. (2010). Apoptotic death of hematopoietic tumor cells through potentiated and sustained adhesion to fibronectin via VLA-4. J Biol Chem 285:7006-7015.
61. Salani R, Neuberger I, Kurman RJ, Bristow RE, Chang HW, Wang TL, Shih IeM. (2007). Expression of extracellular matrix proteins in ovarian serous tumors. Int J Gynecol Pathol 26:141-146.
62. Sengupta S, Nandi S, Hindi ES, Wainwright DA, Han Y, Lesniak MS. (2010). Short hairpin RNA-mediated fibronectin knockdown delays tumor growth in a mouse glioma model. Neoplasia 12:837-847.
63. Siemianowicz K, Gminski J, Francuz T, Syzdol M, Polanska D, Machalski M, Brulinski K, Magiera-Molendowska H. (2001). Fibronectin gene polymorphism in patients with lung cancer. Oncol Rep 8:1289-1292.
64. Singh RD, Haridas N, Patel JB, Shah FD, Shukla SN, Shah PM, Patel PS. (2010). Matrix metalloproteinases and their inhibitors: Correlation with invasion and metastasis in oral cancer. Indian J Clin Biochem 25:250-259.
65. Slack-Davis JK, Atkins KA, Harrer C, Hershey ED, Conaway M. (2009). Vascular cell adhesion molecule-1 is a regulator of ovarian cancer peritoneal metastasis. Cancer Res 69:1469-1476.
66. Steffens S, Schrader AJ, Vetter G, Eggers H, Blasig H, Becker J, Kuczyk MA, Serth J. (2012). Fibronectin 1 protein expression in clear cell renal cell carcinoma. Oncol Lett 3:787-790.
67. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, Jensen LJ, von Mering C. (2011). The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res 39:D561-D568.
68. Takano T, Ito Y, Matsuzuka F, Miya A, Kobayashi K, Yoshida H, Miyauchi A. (2007). Expression of oncofetal fibronectin mRNA in thyroid anaplastic carcinoma. Jpn J Clin Oncol 37:647-651.
69. Torbenson M, Wang J, Choti M, Ashfaq R, Maitra A, Wilentz RE, Boitnott J. (2002). Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol 15:826-830.
70. van der Waal I, de Bree R, Brakenhoff R, Coebergh JW. (2011). Early diagnosis in primary oral cancer: Is it possible? Med Oral Patol Oral Cir Bucal 16:e300-e305.
71. Waalkes S, Atschekzei F, Kramer MW, Hennenlotter J, Vetter G, Becker JU, Stenzl A, Merseburger AS, Schrader AJ, Kuczyk MA, Serth J. (2010). Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer. BMC Cancer 10:503.
72. Wang SJ, Wong G, de Heer AM, Xia W, Bourguignon LY. (2009). CD44 variant isoforms in head and neck squamous cell carcinoma progression. Laryngoscope 119:1518-1530.
73. Wang Z, Han B, Zhang Z, Pan J, Xia H. (2010). Expression of angiopoietinlike 4 and tenascin C but not cathepsin C mRNA predicts prognosis of oral tongue squamous cell carcinoma. Biomarkers 15:39-46.
74. Wang SJ, Bourguignon LY. (2011). Role of hyaluronan-mediated CD44 signaling in head and neck squamous cell carcinoma progression and chemoresistance. Am J Pathol 178:956-963.
75. Warawdekar UM, Zingde SM, Iyer KS, Jagannath P, Mehta AR, Mehta NG. (2006). Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients. Clin Chim Acta 372:83-93.
76. Wei KC, Huang CY, Chen PY, Feng LY, Wu TW, Chen SM, Tsai HC, Lu YJ, Tsang NM, Tseng CK, Pai PC, Shin JW. (2010). Evaluation of the prognostic value of CD44 in glioblastoma multiforme. Anticancer Res 30:253-259.
77. Williams DA, Rios M, Stephens C, Patel VP. (1991). Fibronectin and VLA-4 in haematopoietic stem cell-microenvironment interactions. Nature 352:438-441.
78. Yen CY, Liu SY, Chen CH, Tseng HF, Chuang LY, Yang CH, Lin YC, Wen CH, Chiang WF, Ho CH, Chen HC, Wang ST, Lin CW, Chang HW. (2008). Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan. J Oral Pathol Med 37:271-277.
79. Yen CY, Chen CH, Chang CH, Tseng HF, Liu SY, Chuang LY, Wen CH, Chang HW. (2009). Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. Biomarkers 14:244-249.
80. Zhou J, Nagarkatti PS, Zhong Y, Creek K, Zhang J, Nagarkatti M. (2010). Unique SNP in CD44 intron 1 and its role in breast cancer development. Anticancer Res 30:1263-1272.